NASDAQ:OTIC - Otonomy Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$3.05 -0.15 (-4.69 %)
(As of 08/15/2018 04:00 PM ET)
Previous Close$3.20
Today's Range$3.05 - $3.25
52-Week Range$2.80 - $21.15
Volume82,196 shs
Average Volume319,302 shs
Market Capitalization$107.21 million
P/E Ratio-1.08
Dividend YieldN/A
Beta3.03
Otonomy logoOtonomy, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. In addition, it develops OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties; OTO-5XX, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

Receive OTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OTIC
CUSIPN/A
Phone619-323-2200

Debt

Debt-to-Equity RatioN/A
Current Ratio18.62
Quick Ratio18.62

Price-To-Earnings

Trailing P/E Ratio-1.08
Forward P/E Ratio-1.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.24 million
Price / Sales75.34
Cash FlowN/A
Price / CashN/A
Book Value$3.87 per share
Price / Book0.79

Profitability

EPS (Most Recent Fiscal Year)($2.97)
Net Income$-90,130,000.00
Net Margins-6,640.16%
Return on Equity-56.60%
Return on Assets-51.74%

Miscellaneous

Employees53
Outstanding Shares30,630,000
Market Cap$107.21 million

Otonomy (NASDAQ:OTIC) Frequently Asked Questions

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How were Otonomy's earnings last quarter?

Otonomy Inc (NASDAQ:OTIC) issued its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.06. The biopharmaceutical company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.30 million. Otonomy had a negative net margin of 6,640.16% and a negative return on equity of 56.60%. View Otonomy's Earnings History.

When is Otonomy's next earnings date?

Otonomy is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Otonomy.

What price target have analysts set for OTIC?

4 brokerages have issued 1 year price targets for Otonomy's stock. Their forecasts range from $8.00 to $10.00. On average, they expect Otonomy's share price to reach $8.75 in the next year. This suggests a possible upside of 186.9% from the stock's current price. View Analyst Price Targets for Otonomy.

What is the consensus analysts' recommendation for Otonomy?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy.

Are investors shorting Otonomy?

Otonomy saw a drop in short interest during the month of June. As of June 29th, there was short interest totalling 727,991 shares, a drop of 44.9% from the June 15th total of 1,321,378 shares. Based on an average daily volume of 576,927 shares, the short-interest ratio is currently 1.3 days. Approximately 2.8% of the company's shares are sold short. View Otonomy's Current Options Chain.

Who are some of Otonomy's key competitors?

Who are Otonomy's key executives?

Otonomy's management team includes the folowing people:
  • Dr. Jay B. Lichter, Co-Founder & Chairman (Age 56)
  • Dr. David Allen Weber, Pres, CEO & Director (Age 58)
  • Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 56)
  • Dr. Kathie M. Bishop, Chief Scientific Officer (Age 52)
  • Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel

Has Otonomy been receiving favorable news coverage?

Press coverage about OTIC stock has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Otonomy earned a media and rumor sentiment score of 0.20 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.22 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Otonomy.

Who are Otonomy's major shareholders?

Otonomy's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (4.60%), Renaissance Technologies LLC (4.42%), BlackRock Inc. (2.63%), Millennium Management LLC (1.95%), Bank of New York Mellon Corp (1.63%) and Paloma Partners Management Co (0.45%). Company insiders that own Otonomy stock include Carl Lebel and Eric J Loumeau. View Institutional Ownership Trends for Otonomy.

Which institutional investors are selling Otonomy stock?

OTIC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Citadel Advisors LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Otonomy.

Which institutional investors are buying Otonomy stock?

OTIC stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Paloma Partners Management Co, LMR Partners LLP, Laurion Capital Management LP and Acadian Asset Management LLC. View Insider Buying and Selling for Otonomy.

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $3.05.

How big of a company is Otonomy?

Otonomy has a market capitalization of $107.21 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]


MarketBeat Community Rating for Otonomy (NASDAQ OTIC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.